Payment overview · 2025
General Payments
$205.47
10 reported records · 7 companies
Healthcare provider profile · identity verified
David L Tetrick
Allopathic & Osteopathic Physicians|Internal Medicine · NOBLESVILLE, IN · NPI 1639183874
Verified facts
What the public records show
CMS Open Payments records show David L Tetrick received $205.47 in general payments during 2025 across 10 reported records.
SUN PHARMACEUTICAL INDUSTRIES INC. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $58.04 | 28.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.79 | 18.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.66 | 15.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.62 | 11.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.79 | 11.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.82 | 7.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.75 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.47 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1268 | 283 |
| Levothyroxine Sodium | Levothyroxine Sodium | 854 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 647 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 603 | 135 |
| Furosemide | Furosemide | 499 | 86 |
| Potassium Chloride | Potassium Chloride | 498 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 495 | 92 |
| Eliquis | Apixaban | 494 | 68 |
| Gabapentin | Gabapentin | 394 | 82 |
| Lisinopril | Lisinopril | 393 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 358 | 92 |
| Trazodone Hcl | Trazodone Hcl | 327 | 65 |
| Sertraline Hcl | Sertraline Hcl | 320 | 68 |
| Omeprazole | Omeprazole | 307 | 101 |
| Losartan Potassium | Losartan Potassium | 290 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 261 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 67 |
| Memantine Hcl | Memantine Hcl | 219 | 29 |
| Donepezil Hcl | Donepezil Hcl | 193 | 29 |
| Simvastatin | Simvastatin | 191 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 40 |
| Allopurinol | Allopurinol | 166 | 36 |
| Carvedilol | Carvedilol | 165 | 31 |
| Xarelto | Rivaroxaban | 165 | 23 |
| Spironolactone | Spironolactone | 157 | 33 |
| Metformin Hcl | Metformin Hcl | 154 | 31 |
| Metformin Hcl Er | Metformin Hcl | 154 | 46 |
| Mirtazapine | Mirtazapine | 152 | 34 |
| Finasteride | Finasteride | 150 | 33 |
| Buspirone Hcl | Buspirone Hcl | 142 | 24 |
| Alendronate Sodium | Alendronate Sodium | 122 | 30 |
| Valsartan | Valsartan | 110 | 37 |
| Amiodarone Hcl | Amiodarone Hcl | 109 | 18 |
| Famotidine | Famotidine | 109 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 107 | 18 |
| Torsemide | Torsemide | 100 | 24 |
| Baclofen | Baclofen | 99 | 15 |
| Montelukast Sodium | Montelukast Sodium | 93 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 24 |
| Humalog | Insulin Lispro | 89 | 18 |
| Divalproex Sodium | Divalproex Sodium | 87 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 24 |
| Atenolol | Atenolol | 84 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 82 | 17 |
| Nystatin | Nystatin | 80 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 19 |
| Ezetimibe | Ezetimibe | 75 | 21 |
| Meloxicam | Meloxicam | 72 | 24 |
| Farxiga | Dapagliflozin Propanediol | 71 | suppressed |
| Myrbetriq | Mirabegron | 71 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 25 |
| Bupropion Xl | Bupropion Hcl | 66 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Jardiance | Empagliflozin | 63 | 11 |
| Tradjenta | Linagliptin | 63 | suppressed |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 12 |
| Prednisone | Prednisone | 58 | 17 |
| Gemtesa | Vibegron | 57 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | suppressed |
| Latanoprost | Latanoprost | 55 | 14 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 18 |
| Ondansetron Odt | Ondansetron | 53 | 35 |
| Cephalexin | Cephalexin | 52 | 34 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 12 |
| Nyamyc | Nystatin | 51 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | 18 |
| Glimepiride | Glimepiride | 48 | 12 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 13 |
| Anastrozole | Anastrozole | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 42 | suppressed |
| Ozempic | Semaglutide | 42 | 11 |
| Sotalol | Sotalol Hcl | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 12 |
| Loperamide | Loperamide Hcl | 39 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 18 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | 24 |
| Synthroid | Levothyroxine Sodium | 32 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 13 |
| Morphine Sulfate | Morphine Sulfate | 30 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 19 |
| Octreotide Acetate | Octreotide Acetate | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 19 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 21 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 22 | 22 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Lorazepam Intensol | Lorazepam | 22 | 22 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 21 | 21 |
| Azithromycin | Azithromycin | 21 | 20 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Nystop | Nystatin | 17 | 13 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 13 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $205.47 · 10 records | SUN PHARMACEUTICAL INDUSTRIES INC. | Cologuard Collection Kit, EVENITY, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, VRAYLAR, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error